Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
CHESTERBROOK, Pa., March 07, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN) today announced that it will be presenting at the Cowen and Company 38th Annual Healthcare Conference on Wednesday,...
-
– OLINVO™ (oliceridine) Injection New Drug Application submitted and accepted for review by FDA, with PDUFA date of November 2, 2018 – – Company to host conference call at 8:00 am EST today – ...
-
CHESTERBROOK, Pa., March 02, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN) today announced that the independent Compensation Committee of the Board of Directors of the Company approved,...
-
CHESTERBROOK, Pa., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN) today announced that it will host a conference call on Wednesday, March 7, 2018 at 8:00 am EST to review financial...
-
CHESTERBROOK, Pa., Feb. 02, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN) today announced the promotion of Carrie L. Bourdow from Senior Vice President and Chief Commercial Officer to...
-
CHESTERBROOK, Pa., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application...
-
– New ATHENA data show OLINVO effectiveness with promising safety/tolerability in key target procedures – – Positive interim data for Phase 1 study of investigational migraine treatment TRV250 leads...
-
Trevena Announces Submission of New Drug Application to U.S. FDA for OLINVO™ (oliceridine injection)
CHESTERBROOK, Pa., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN) today announced that it has recently submitted its New Drug Application (NDA) for OLINVOTM (oliceridine injection) to...
-
CHESTERBROOK, Pa., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN) today announced that it will host a conference call and webcast on Tuesday, November 7, 2017 at 8:00 am EST to review...
-
– American Society of Anesthesiologists Annual Meeting presentations highlight OLINVO data from positive Phase 3 trials – – OLINVO Phase 2b data published in Journal of Pain Research – CHESTERBROOK,...